LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation (“Centurion”). All of Centurion’s assets will be absorbed by the Company via a merger agreement. Centurion’s assets consist of the high-potential LADR platform for the concentration and localized delivery of cancer therapeutics. The Centurion board of directors will also be terminated.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, the Company’s Chairman and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is taking place virtually September 13-15, 2021.
INDIANAPOLIS--(BUSINESS WIRE)--TRIMEDX, an industry-leading provider of clinical engineering, medical device cybersecurity and clinical asset management solutions to healthcare providers, announced the acquisition of Centurion Service Group, a full-service surplus medical equipment management company, to expand its Clinical Asset Management offering. The added capabilities of Centurion will allow TRIMEDX clients to gain maximum value from their excess medical equipment through Centurion auction services, positively impacting operational expenses, maximizing resources to improve patient care and optimizing clinical asset capital spend while also supporting environmental sustainability of dispositioned medical equipment.
The US Food and Drug Administration (FDA) classified on Friday a QIAGEN recall of filter-tips used with two QIAGEN assays indicated for monitoring treatment of a common virus and evaluating blood cancers, as well as a Centurion Medical Products recall of airways kits containing Teleflex endotracheal tubes and connectors.
The US Food and Drug Administration (FDA) last month warned Indian drugmaker Centurion Laboratories over good manufacturing practice (GMP) violations observed at the company’s Gujarat facility last October.
Enforcement Report - Week of September 20, 2017
Centurion Labs has recalled two lots of cold and allergy meds after the US FDA warned they may have been made at a Pharmatech LLC plant linked to a Burkholderia cepacia outbreak.
Centurion Labs Issues Voluntary Nationwide Recall of Ninjacof & Ninjacof A
APIs made by Laxachem Organics pvt ltd were not the source of bacteria in Pharmatech laxatives linked to a spate of Burkholderia cepacia infections according to the US Food and Drug Administration (FDA).